Bone Mineral Density Changes in HIV-positive Females With Osteopenia Switching to Raltegravir
Information source: University of Turin, Italy
ClinicalTrials.gov processed this data on August 23, 2015 Link to the current ClinicalTrials.gov record.
Condition(s) targeted: HIV Infection; Osteopenia
Intervention: raltegravir and atazanavir and ritonavir (Drug); tenofovir/emtricitabine and atazanavir and ritonavir (Drug)
Phase: Phase 4
Status: Recruiting
Sponsored by: Giovanni Di Perri Official(s) and/or principal investigator(s): Giovanni Di Perri, MD, PhD, Principal Investigator, Affiliation: University of Turin, Italy
Overall contact: Andrea Calcagno, MD, Phone: +390114393884, Email: andrea.calcagno@unito.it
Summary
Given the high prevalence of bone alteration in the course of HIV infection or
antiretroviral treatment and the favourable properties of raltegravir the investigators
designed this pilot randomized and controlled study. Adult female HIV-positive patients on
successful treatment with tenofovir/emtricitabine plus atazanavir plus ritonavir will be
randomized either to continue such a regimen or to switch to raltegravir plus atazanavir
plus ritonavir. Bone mineral density changes will be compared in the two groups at 48 weeks:
the hypothesis is that removing tenofovir and using tenofovir will increase bone mineral
density at 48 weeks.
Clinical Details
Official title: Switching HIV-positive Women on Tenofovir/Emtricitabine Plus Boosted Atazanavir to RALtegravir Plus Boosted ATazanavir: A Pilot Randomized Clinical Trial Investigating 48-weeks Changes in Bone Mineral Density
Study design: Allocation: Randomized, Endpoint Classification: Safety/Efficacy Study, Intervention Model: Parallel Assignment, Masking: Open Label, Primary Purpose: Treatment
Primary outcome: Variations from baseline in DEXA-measured bone mineral density (t-score, spine and femur)
Secondary outcome: variations from baseline in CTX (C-terminal telopeptide of type I collagen) and OC (Osteocalcin)To assess the variation in renal function
Detailed description:
The objective is to assess the improvement in Bone Mineral Density and markers of bone
turnover in women on TDF/FTC (tenofovir disoproxil fumarate/ emtricitabine)+ ATV/r
(atazanavir/ritonavir) in a switch arm (RAL (raltegravir) + ATV/r) vs. an unchanged arm
(TDF/FTC + ATV/r).
The clinical hypothesis is that removing tenofovir (associated to a boosted PI, and
therefore in the worst clinical scenario) in both pre-menopausal and menopausal women could
be beneficial and being associated with reduced bone mineral density loss measured by DEXA
(densitometry)scan scores and markers of bone turnover. The underlying mechanism is believed
to be the reduction in hyper-phosphaturia induced by proximal tubular dysfunction: therefore
measuring renal tubular markers and hormones involved in calcium and phosphorus homeostasis
(such as vitamin D and parathormone) will explain the suspected mechanism.
Eligibility
Minimum age: 18 Years.
Maximum age: 80 Years.
Gender(s): Female.
Criteria:
Inclusion Criteria:
- Adult HIV-positive female patients;
- osteopenia (t-score from -1 to -2. 5);
- On antiretroviral treatment with tenofovir/emtricitabine and atazanavir/ritonavir
(300/100 mg) for at least six months;
- Plasma HIV RNA below 50 copies/ml since six months;
- Premenopausal women: female patients at any phase of the reproductive period with
regular menstrual cycles and normal FSH (< 25 ng/mL) That would probably exclude
patients with ovarian or endocrinological dysfunctions. Pre and postmenopausal should
be therefore well-characterized.
- Women in menopausal period (the menopause was defined as 12 months of amenorrhoea
without any pathological or physiological cause and using the endocrinological
definition of ovary insufficiency (LH (Luteic hormone) >25ng/mL, FSH (follicule
stimulating hormone)>25ng/mL and E2 (Estradiol)<30ng/mL).
- Each premenopausal sexually active subject of child-bearing potential must agree to
use a medically accepted method of contraception while receiving protocol-specified
medication and for 3 months after stopping the medication. Medically accepted methods
of contraception include condoms (male or female) with or without a spermicidal
agent, diaphragm or cervical cap with spermicide, medically prescribed IUD
(intrauterine device), inert or copper-containing IUD, hormone-releasing IUD,
systemic hormonal contraceptive, and surgical sterilization (eg, hysterectomy or
tubal ligation).
- Postmenopausal women are not required to use contraception.
Exclusion Criteria:
- History or current evidence of any condition, therapy, laboratory abnormality or
other circumstance that might confound the results of the study, or interfere with
the patient's participation for the full duration of the study, such that it is not
in the best interest of the patient to participate.
- Documented resistance to Raltegravir or/and Atazanavir.
- Patient with significant hypersensitivity or other contraindication to any of the
components of the study drugs.
- Patient has a current (active) diagnosis of acute hepatitis due to any cause
- Patient with coinfection HIV/HBV (Human Hepatitis virus B)
- Liver cirrhosis
- Osteoporosis (t-score less than 2. 5).
- Secondary endocrinological cause of low BMD (Bone mineral density)
- Chronic steroid intake;
- Chronic kidney disease (estimated glomerular filtration rate below 60 ml/min);
- Concomitant use of bisphosphonate.
Locations and Contacts
Andrea Calcagno, MD, Phone: +390114393884, Email: andrea.calcagno@unito.it
University of Milano, Milano, Italy; Not yet recruiting Stefano Rusconi, MD, Email: stefano.rusconi@unimi.it Massimo Galli, MD, PhD, Principal Investigator Stefano Rusconi, MD, Sub-Investigator
University of Torino, Torino, Italy; Recruiting Andrea Calcagno, MD, Phone: +390114393884, Email: andrea.calcagno@unito.it Stefano Bonora, MD, Sub-Investigator Giovanni Di Perri, MD, PhD, Principal Investigator Andrea Calcagno, MD, Sub-Investigator
Additional Information
Starting date: September 2014
Last updated: December 2, 2014
|